Neurotransmitter exchange in patients with skin melanoma

Cover Page

Cite item


Aim. To study peculiarities of neurotransmitter exchange in patients with skin melanoma.

Methods. Neurotransmitters (adrenaline, noradrenaline, dopamine) and their ratio in blood plasma were determined in 111 patients with skin melanoma and 38 healthy donors. The patients were divided into 3 groups: primary patients, patients with relapse of the disease and without relapse. To exclude the influence of undesirable factors (stress and physical exertion) on the level of neurotransmitters, the patients’ blood was drawn 1 day after admission in the morning on an empty stomach. Adrenaline, noradrenaline and dopamine concentration in the blood plasma was determined with the use of high-yield liquid chromatography with electrochemical detection.

Results. Analyzing noradrenaline/adrenaline ratio in the studied patients’ groups we noted significant unidirectionality of the changes in the form of increased noradrenaline and decreased adrenergic link of sympathoadrenal system i.e. in patients with skin melanoma mediator link dominates over hormonal link. Evaluation of noradrenaline/dopamine and dopamine ratio demonstrated that in normal or even increased level of dopamine adrenaline and noradrenaline levels are below normal that can indicate dysfunction of enzyme systems involved in neurotransmitter exchange and/or their accumulation in tumors. Maximal disorders of neurotransmitter exchange were registered in the group of patients with the disease relapse.

Conclusion. Patients with skin melanoma have imbalance of sympathoadrenal system that creates the perspective for the use of neuropharmacological drugs and psychotherapy in the treatment and rehabilitation of such patients.

About the authors

Z A Afanas’eva

Kazan State Medical Academy

Author for correspondence.
Kazan, Russia

L K Mukhamatgaleeva

Kazan State Medical Academy; Republican Oncology Center

Kazan, Russia; Yoshkar-Ola, Russia

F S Bilalov

Bashkir State Medical University, LLC «MedLab»

Ufa, Russia

I G Gataullin

Kazan State Medical Academy

Kazan, Russia

V P Potanin

Kazan State Medical Academy

Kazan, Russia

A K Ismagilov

Kazan State Medical Academy

Kazan, Russia


  1. Абрамов В.В., Егоров Д.Н., Вардосанидзе В.К., Козлов В.В. Нервная и иммунная система в канцерогенезе. Новосибирск: СО РАМН. 1998; 102 с.
  2. Егоров Д.Н., Соловьёва И.Г., Черенкова М.М. и др. Влияние вегетативной регуляции на отдалённые результаты радикального хирургического лечения рака желудка. Сибир. онкол. ж. 2006; 4 (20): 20-26.
  3. Li S., Sun Y., Gao D. Role of the nervous system in cancer metastasis (Review). Oncol. Letters. 2013; 5 (4): 1101-1111. doi: 10.3892/ol.2013.1168.
  4. Schuller H.M. Neurotransmission and cancer: implications for prevention and therapy. Anticancer Drugs. 2008; 19 (7): 655-671. doi: 10.1097/CAD.0b013e3283025b58.
  5. Guo K., Ma Q., Wang L. et al. Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. Oncol. Reports. 2009; 22 (4): 825-830. doi: 10.3892/or_00000505.
  6. Tilan J., Kitlinska J. Sympathetic neurotransmitters and tumor angiogenesis - link between stress and cancer progression. J. Oncol. 2010; 2010: 539706. doi: 10.1155/2010/539706.
  7. Кашулина А.П., Соколова И.И., Терещенко И.П., Попов М.И. Катехоламины в эритроцитах онкологических больных. Патол. физиол. и эксперим. терап. 1990; (1): 39-40.
  8. Клименко Е.М., Шевелёва В.С., Мельников Р.А. Содержание катехоламинов в опухолях желудочно-кишечного тракта. Вопр. онкол. 1983; 29 (2): 19-25.
  9. Мельников Р.А., Попова Р.Т., Шевелёва В.С. Состояние симпатико-адреналовой системы у больных раком молочной железы. Вопр. онкол. 1981; 27 (12): 9-14.
  10. Ойфе Г.Р. О соотношении содержания катехоламинов в крови и в моче у больных злокачественными новообразованиями пищеварительного тракта в условиях физиологической нагрузки. Клин. хир. 1971; (5): 69-72.
  11. Тарутинов В.И., Палюх А.Р., Винницкий В.Б. и др. Нарушение функции симпатоадреналовой системы у больных раком пищевода и желудка. Вопр. онкол. 1984; 30 (8): 60-67.
  12. Шевелёва В.С., Мельников Р.А., Симонов Н.Н. Состояние симпатоадреналовой системы у больных злокачественными опухолями желудочно-кишечного тракта. Вопр. онкол. 1980; 26 (8): 35-41.
  13. Шульга Н.И. Функциональное состояние надпочечников у больных раком лёгкого. Вопр. онкол. 1980; 26 (8): 32-34.
  14. Yang E.V., Sood A.K., Chen M. et al. Norepinephrine upregulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res. 2006; 66: 10357-10364. doi: 10.1158/0008-5472.CAN-06-2496.
  15. Sood A.K., Bhatty R., Kamat A.A. et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin. Cancer Res. 2006; 12: 369-375. doi: 10.1158/1078-0432.CCR-05-1698.
  16. Lutgendorf S.K., Cole S., Costanzo E. et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin. Cancer Res. 2003; 9 (12): 4514-4521. PMID: 14555525.
  17. Yang E.V. Role for catecholamines in tumor progression. Possible use for β-blockers in the treatment of cancer. Cancer Biol. Ther. 2010; 10 (1): 30-32. doi: 10.4161/cbt.10.1.12260.
  18. Moretti S., Massi D., Farini V. et al. β-Adrenoceptors are upregulated in human melanoma and their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines. Lab. Invest. 2013; 93 (3): 279-290. doi: 10.1038/labinvest.2012.175.
  19. Asada M., Ebihara S., Numachi Y. et al. Reduced tumor growth in a mouse model of schizophrenia, lacking the dopamine transporter. Intern. J. Cancer. 2008; 123 (3): 511-518. doi: 10.1002/ijc.23562.
  20. Демидов Л.В., Соколов Д.В., Булычёва И.В. и др. Совершенствование методов диагностики меланомы кожи. Вестн. РОНЦ им. Н.Н. Блохина РАМН. 2007; 18 (1): 36-41.
  21. Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2011 г. (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена. 2013; 289 с.
  22. Miller A.J., Mihm M.C. Melanoma. N. Engl. J. Med. 2006; 355: 51-65. doi: 10.1056/NEJMra052166.

© 2017 Afanas’eva Z.A., Mukhamatgaleeva L.K., Bilalov F.S., Gataullin I.G., Potanin V.P., Ismagilov A.K.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies